Evaluating LLMs in non-metastatic melanoma care: a comparative analysis.

BACKGROUND

Malignant melanoma is an aggressive skin cancer with rising incidence. Accurate early staging and standardized treatment are crucial for prognosis. This study evaluates seven large language models (LLMs)-including GPT-5.2, Gemini-3.1, and medically enhanced models-in assisting non-metastatic melanoma management amid clinical complexities.

METHODS

Employing a prospective, simulated expert-blinded design, 59 virtual cases across TNM stages, ages, and comorbidities were assessed. Multiple senior oncologists independently evaluated model outputs using a 6-point Likert scale for staging accuracy, treatment rationality, and protocol standardization.

RESULTS

GPT-5.2 (5.56 ± 1.12) and Gemini-3.1 (5.25 ± 1.3) achieved the highest staging accuracy, while AntAngelMed performed worst (2.93 ± 1.67). Performance declined significantly in complex Stage III cases. GPT-5.2 and Gemini-3.1 also led in treatment rationality, showing stability, whereas model performances converged in early stages but diverged in advanced ones. Gemini-3.1 excelled in protocol standardization (5.17 ± 0.57), though some models posed risks like insufficient surgical margin recommendations.

CONCLUSION

Leading LLMs demonstrate potential for high-quality melanoma management but exhibit inconsistent performance influenced by architecture and case complexity, with reduced reliability in advanced stages. Future tools require risk-stratified guidelines and real-world validation to improve patient outcomes.